Wang et al., 2020 - Google Patents
Characterization of an asymptomatic cohort of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected individuals outside of Wuhan, ChinaWang et al., 2020
View HTML- Document ID
- 14018882466113025038
- Author
- Wang Y
- He Y
- Tong J
- Qin Y
- Xie T
- Li J
- Li J
- Xiang J
- Cui Y
- Higgs E
- Xiang J
- Publication year
- Publication venue
- Clinical Infectious Diseases
External Links
Snippet
Purpose We aimed to further clarify the epidemiological and clinical characteristics of asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Methods We identified close contacts of confirmed coronavirus disease 2019 (COVID-19) …
- 241001678559 COVID-19 virus 0 title abstract description 55
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
- G06F19/322—Management of patient personal data, e.g. patient records, conversion of records or privacy aspects
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
- G06Q50/24—Patient record management
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/36—Computer-assisted acquisition of medical data, e.g. computerised clinical trials or questionnaires
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Characterization of an asymptomatic cohort of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected individuals outside of Wuhan, China | |
Lee et al. | Testing for SARS-CoV-2: can we stop at 2? | |
Van Vinh Chau et al. | The natural history and transmission potential of asymptomatic severe acute respiratory syndrome coronavirus 2 infection | |
Wang et al. | C-reactive protein level may predict the risk of COVID-19 aggravation | |
Wang et al. | Clinical outcomes in 55 patients with severe acute respiratory syndrome coronavirus 2 who were asymptomatic at hospital admission in Shenzhen, China | |
Xiao et al. | Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients | |
Wang et al. | Characterization of an asymptomatic cohort of SARS-COV-2 infected individuals outside of Wuhan, China | |
Ayele et al. | Prevalence and associated factors of treatment failure among HIV/AIDS patients on HAART attending University of Gondar Referral Hospital Northwest Ethiopia | |
Hao et al. | Decreased B cells on admission associated with prolonged viral RNA shedding from the respiratory tract in coronavirus disease 2019: a case-control study | |
Uyeki et al. | Low sensitivity of rapid diagnostic test for influenza | |
Puthanakit et al. | Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy | |
Lin et al. | Early risk factors for the duration of severe acute respiratory syndrome coronavirus 2 viral positivity in patients with coronavirus disease 2019 | |
MacNeil et al. | Transmission of atypical varicella-zoster virus infections involving palm and sole manifestations in an area with monkeypox endemicity | |
Guan et al. | Effectiveness and safety of an inactivated enterovirus 71 vaccine in children aged 6–71 months in a phase IV study | |
Ho et al. | Mild illness associated with severe acute respiratory syndrome coronavirus infection: lessons from a prospective seroepidemiologic study of health-care workers in a teaching hospital in Singapore | |
Kojima et al. | Changing severity and epidemiology of adults hospitalized with coronavirus disease 2019 (COVID-19) in the United States after introduction of COVID-19 vaccines, March 2021–August 2022 | |
Baltas et al. | Post-vaccination coronavirus disease 2019: a case-control study and genomic analysis of 119 breakthrough infections in partially vaccinated individuals | |
Tsakok et al. | Diagnostic accuracy of initial chest radiograph compared to SARS-CoV-2 PCR in patients with suspected COVID-19 | |
Nie et al. | Epidemiological and clinical characteristics of 671 COVID-19 patients in Henan Province, China | |
Morjaria et al. | West Nile virus central nervous system infection in patients treated with rituximab: implications for diagnosis and prognosis, with a review of literature | |
Zhou et al. | Epidemiological and clinical features of 201 COVID-19 patients in Changsha city, Hunan, China | |
Hatta et al. | Post-tsunami outbreaks of influenza in evacuation centers in Miyagi Prefecture, Japan | |
Sigurbergsdóttir et al. | Autoimmunity, infections, and the risk of monoclonal gammopathy of undetermined significance | |
Stufano et al. | Work-related human T-lymphotropic virus 1 and 2 (HTLV-1/2) infection: a systematic review | |
Ni et al. | Clinical features, treatment, and outcome of psittacosis pneumonia: A multicenter study |